roe-SOO-va-sta-tin 
2 risk factors for cardiovascular disease])50 yr for men; 60 yr for women), hsCRP 2 mg/L, and the presence of 1 risk factor for cardiovascular disease (hypertension, low HDL-C, smoking, or premature family history of coronary heart disease).Absorption: 20% absorbed following oral administration.
Distribution: Unknown.
Metabolism/Excretion: 10% metabolized, 90% excreted unchanged in feces.
Half-life: 19 hr.
Contraindicated in:
Use Cautiously in:
CNS: amnesia, confusion, memory loss, weakness.
GI: abdominal pain, constipation, drug-induced hepatitis, ↑ liver function tests, nausea.
Derm: rash.
Endo: hyperglycemia.
Hemat: thrombocytopenia.
Metab: RHABDOMYOLYSIS, immune-mediated necrotizing myopathy, myalgia.
Drug-Drug:
Renal Impairment
Therapeutic Classification: lipid-lowering agents
Pharmacologic Classification: hmg coa reductase inhibitors (statins)
NDC Code*
